论文部分内容阅读
我们在开展中西药结合防治心血管疾病的药物研究工作中,于1973年采用中草药毛冬青(Ilex Pubesceas Hook.et Arn.)、化学合成药安妥明(Atromid-S)以及卵磷酯、抗坏血酸、盐酸吡多辛、菸酸、肌醇等,制成中西结合防治冠心病新药——心脉宁糖衣片。两年多来在广州中山医学院第二、三附属医院,广州部队总医院、广东省中医院等15个医疗单位广泛的临床应用,证实心脉宁对治疗心绞痛缓解率达85％,具有较明显地降低血清胆固醇、甘油三酯、β——酯蛋白的比率,及扩张冠状动脉的作用,对心绞痛、头晕、心悸、气促等有明显的缓解作用。且副作用少,无明显的毒性反应,是目前防治冠心病较好的药物之一。为了密切结合临床药理学的研究,我们着重验证心脉宁对心绞痛等的药理作用。
In 1973, we conducted research on Chinese and Western medicines for the prevention and treatment of cardiovascular disease. In 1973, we used Ilex Pubesceas Hook. et Arn., Atromid-S, and lecithin, ascorbic acid, Pyridoxine hydrochloride, nicotinic acid, inositol, etc., made of Chinese and Western combination of coronary heart disease prevention and control drugs - Xinxinning sugarcoated tablets. Over the past two years, a wide range of clinical applications in 15 medical units, including the Second and Third Affiliated Hospitals of Guangzhou Sun Yat-Sen Medical College, General Hospital of Guangzhou Troops, and Guangdong Provincial Hospital of Traditional Chinese Medicine, have confirmed that the remission rate of Xin Mai Ning to treat angina is 85%. Significantly reduce the serum cholesterol, triglyceride, β - ester protein ratio, and the role of coronary artery expansion, an obvious relief of angina, dizziness, heart palpitations, shortness of breath and so on. With fewer side effects and no obvious toxicity, it is one of the better drugs for preventing and treating coronary heart disease. In order to closely integrate clinical pharmacology studies, we focused on the pharmacological effects of Xinmaining on angina pectoris.